August 1st, 2024
Berkeley, California, Newomics Inc., a biotechnology company specializing in mass spectrometry solutions for molecular detection, announces a collaboration with Agilent, a leading company with diverse life science research and diagnostics solutions. Together they are developing a novel LC/MS platform designed for drug discovery and identification of new druggable targets for the pharma/biopharma industry and research institutions.
Newomics and Agilent have entered into a co-marketing agreement combining Newomics’s UniESI product line with Agilent’s Q-TOF and triple quad mass spectrometers. The joint UniESI-MS platform delivers exceptional sensitivity, robustness, and reproducibility, enabling high-throughput analysis of small biological sample volumes. Applications include proteins, oligonucleotides, small molecules, and beyond.
“Our agreement is built upon the close collaboration between our respective teams over the last several years. We look forward to partnering with Newomics to develop workflows that leverage the Newomics UniESI system on Agilent mass spectrometers. These diverse bioanalytical applications will meet our various customer needs,” said Jennifer Gushue, Ph.D., Associate Vice President of MS Marketing, Agilent Technologies, Inc.
“We are excited to collaborate further with Agilent,” said Daojing Wang, Ph.D., Newomics Founder and CEO. “Our UniESI ion source featuring differentiating M3 emitter and MEA chip, combined with an Agilent LC/MS system, has demonstrated successful applications in several emerging mass spectrometry fields, including native spray mass spectrometry and metabolomics. We are grateful to several top biopharma companies who embraced our UniESI-MS platform as early access customers.”
